INFU Pemfailan SEC - InfuSystem Holdings, Inc.- Laporan Tahunan, Penyata Proksi, Prospektus

Statistik Asas

LEI	549300F58N8PHJ4QUI59
CIK	1337013

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to InfuSystem Holdings, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.

August 5, 2025	EX-99.1	InfuSystem Reports Second Quarter 2025 Financial Results Record Net Revenues of $36.0 million Representing 7% Growth from the Prior Year Net income of $2.6 million, up 262% Adjusted EBITDA (non-GAAP) of $8.0 million, up 32% Adjusted EBITDA (non-GAAP) Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports Second Quarter 2025 Financial Results Record Net Revenues of $36.0 million Representing 7% Growth from the Prior Year Net income of $2.6 million, up 262% Adjusted EBITDA (non-GAAP) of $8.0 million, up 32%
August 5, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2025 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-35020 INF
August 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 5, 2025 InfuSystem Holding UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 5, 2025 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
July 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 29, 2025 InfuSystem Holdings UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 29, 2025 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commi
July 29, 2025	EX-99.1	InfuSystem to Report Second Quarter 2025 Financial Results on August 5, 2025 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Second Quarter 2025 Financial Results on August 5, 2025 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, July 29, 2025 — InfuSystem Holdings, In
July 17, 2025	EX-10.1	Second Amendment to Credit Agreement dated as of July 15, 2025 by and among InfuSystem Holdings, Inc., InfuSystem, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A. as administrative agent for the lenders. Exhibit 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT THIS SECOND AMENDMENT TO CREDIT AGREEMENT, dated as of July 15 2025 (this “Amendment”), is by and among INFUSYSTEM HOLDINGS, INC. (successor in interest to IFC LLC and InfuSystem Holdings USA, Inc.) and INFUSYSTEM, INC. (successor in interest to First Biomedical, Inc.) (collectively, the "Borrowers"), the lenders party hereto (collectively, the “Le
July 17, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): 07/15/2025 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commissi
June 12, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) InfuSystem Holdings, Inc.
June 12, 2025	S-8	As filed with the Securities and Exchange Commission on June 12, 2025 As filed with the Securities and Exchange Commission on June 12, 2025 Registration No.
June 3, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 29, 2025 InfuSystem Holdings, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 29, 2025 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commis
June 3, 2025	EX-3.1	Second Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on June 3, 2025). Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INFUSYSTEM HOLDINGS, INC. InfuSystem Holdings, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows; 1.The name of the corporation is “InfuSystem Holdings, Inc.”; 2.The corporation’s original Certificate of Incorporation was filed with i
June 3, 2025	EX-10.1	SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Second Amended and Restated Employment Agreement (“Agreement”) between InfuSystem Holdings, Inc., a Delaware corporation (the “Company”), and Carrie Lachance, an individual (“Employee”) is entered into on May 29, 2025 but effective as of the Effective Date. WHEREAS, the Company wishes to retain Employee’s services to work for the C
May 20, 2025	EX-10.1	Second Amendment to InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-35020) as filed with the Commission on May 20, 2025). Exhibit 10.1 SECOND AMENDMENT TO THE INFUSYSTEM HOLDINGS, INC. 2021 EQUITY INCENTIVE PLAN THIS SECOND AMENDMENT to the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (the "Plan") was adopted by the Board of Directors (the “Board”) on March 31, 2025 and approved by the stockholders of InfuSystem Holdings, Inc. (the “Company”) on [, 2025]. WHEREAS, the Company maintains the Plan to (i) attract
May 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 15, 2025 InfuSystem Holdings, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 15, 2025 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commis
May 9, 2025	EX-99.1	Investor Presentation May 9, 2025 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking s Investor Presentation May 9, 2025 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amen
May 9, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2025 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commiss
May 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2025 InfuSystem Holdings, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2025 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commiss
May 8, 2025	EX-99.1	InfuSystem Reports First Quarter 2025 Financial Results Record Net Revenues of $34.7 million Representing 9% Growth from the Prior Year Net loss of $0.3 million Adjusted EBITDA (non-GAAP) of $6.3 million, up 64% Adjusted EBITDA (non-GAAP) margin expa Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports First Quarter 2025 Financial Results Record Net Revenues of $34.7 million Representing 9% Growth from the Prior Year Net loss of $0.3 million Adjusted EBITDA (non-GAAP) of $6.3 million, up 64% Adjusted EBI
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2025 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-35020 IN
May 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 1, 2025 InfuSystem Holdings, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 1, 2025 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commiss
May 1, 2025	EX-99.1	InfuSystem to Report First Quarter 2025 Financial Results on May 8, 2025 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report First Quarter 2025 Financial Results on May 8, 2025 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, May 1, 2025 — InfuSystem Holdings, Inc. (NY
April 10, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
April 1, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
April 1, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 31, 2025 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
April 1, 2025	EX-10.1	Separation Agreement, dated March 31, 2025, by and between the Company and Richard DiIorio (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on April 1, 2025). Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (this “Separation Agreement”) is entered into by and between Richard A. DiIorio (“Executive” or “you”) and InfuSystem Holdings, Inc., a Delaware corporation (the “Company”). In consideration of the promises and the mutual covenants set forth herein, and for other good and valuable consideration, the receipt and suf
April 1, 2025	EX-99.1	InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer The Company Reaffirms Full Year 2025 Guidance: Revenue Growth of 8-10% and Adjusted EBITDA (non-GAAP) margin greater than 18.8% Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer The Company Reaffirms Full Year 2025 Guidance: Revenue Growth of 8-10% and Adjusted EBITDA (non-GAAP) margin greate
March 11, 2025	EX-97.1	InfuSystem Holdings, Inc. Policy for the Recovery of Erroneously Awarded Compensation, dated as of October 2, 2023 EXHIBIT 97.1 INFUSYSTEM HOLDINGS, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1.Purpose. The purpose of this Policy is to describe certain circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to the Company Group. Each Executive Officer must sign an acknowledgement or other agreement pursuant to which such Executive Off
March 11, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35020 INFUSYSTEM
March 11, 2025	EX-19.1	nfuSystem Holdings, Inc. Insider Trading Policy EXHIBIT 19.1 INFUSYSTEM HOLDINGS, INC. INSIDER TRADING AND INFORMATION DISCLOSURE POLICY AS AMENDED AND RESTATED ON JANUARY 19, 2024 INTRODUCTION This Policy explains the requirements and procedures to be followed by employees, officers, and directors of InfuSystem Holdings, Inc. and its subsidiaries (“InfuSystem”) when trading in InfuSystem securities (and, in some cases, the securities of other
March 11, 2025	EX-21.1	Subsidiaries of InfuSystem Holdings, Inc. EXHIBIT 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization InfuSystem, Inc. Delaware 1
March 4, 2025	EX-99.1	InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2024 Full Year 2024 vs. Full Year 2023: Record Net Revenues: $134.9 million, a 7% increase Patient Services Revenue: $80.4 million - Device Solutions Revenue: $54 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2024 Full Year 2024 vs. Full Year 2023: Record Net Revenues: $134.9 million, a 7% increase Patient Services Revenue: $80.4 million - Dev
March 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 4, 2025 InfuSystem Holdings UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 4, 2025 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commi
February 25, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 25, 2025 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
February 25, 2025	EX-99.1	InfuSystem to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, February 25, 2025 — InfuSy
January 22, 2025	EX-99	AGREEMENT Exhibit A AGREEMENT The undersigned agree that this Amendment No. 4 to Schedule 13D, dated January 22, 2025, relating to the Common Stock, par value $0.0001 per share, of InfuSystem Holdings, Inc. shall be filed on behalf of the undersigned. Dated: January 22, 2025 Sansone Advisors, LLC By: /s/ Christopher Sansone Name: Christopher Sansone Title: Managing Member Sansone Capital Management, LLC By:
January 22, 2025	EX-99	Schedule of Transactions in the Shares Exhibit B Schedule of Transactions in the Shares Trade Date Purchase/Sale Quantity Price 12/9/24 Sale 1,427 $9.
December 9, 2024	SC 13D/A	INFU / InfuSystem Holdings, Inc. / SANSONE ADVISORS, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
December 6, 2024	SC 13D/A	INFU / InfuSystem Holdings, Inc. / Shuda Scott - SC 13D/A Activist Investment SC 13D/A 1 infu13d4241206.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* InfuSystem Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45685K102 (CUSIP Number) Scott A Shuda Meridian OHC Partners, LP 425 Weed Street New Canaan, CT 068
December 4, 2024	EX-99.1	Investor Presentation December 4, 2024 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-look Investor Presentation December 4, 2024 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
December 4, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 4, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
November 22, 2024	EX-99.1	InfuSystem to Present at Sidoti Small Cap Conference on December 4, 2024 Investor Presentation to be held at 10:00 a.m. Eastern Time EX-99.1 2 exhibit99111-22x2024sidoti.htm EX-99.1 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Present at Sidoti Small Cap Conference on December 4, 2024 Investor Presentation to be held at 10:00 a.m. Eastern Time Rochester Hills, Mic
November 22, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 22, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
November 18, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 12, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
November 18, 2024	EX-99.1	InfuSystem Appoints Ronald Hundzinski to the Board of Directors Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Appoints Ronald Hundzinski to the Board of Directors Rochester Hills, Michigan, November 18, 2024 - InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading
November 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2024 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-3502
November 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
November 7, 2024	EX-99.1	InfuSystem Reports Third Quarter 2024 Financial Results Record Net Revenues of $35.3 million Representing 11% Growth from the Prior Year Net income of $1.8 million, an increase of 162% Adjusted EBITDA (non-GAAP) margin expanded by 2.8% to 22% Reaffir Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports Third Quarter 2024 Financial Results Record Net Revenues of $35.3 million Representing 11% Growth from the Prior Year Net income of $1.8 million, an increase of 162% Adjusted EBITDA (non-GAAP) margin expan
October 31, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 31, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
October 31, 2024	EX-99.1	InfuSystem to Report Third Quarter 2024 Financial Results on November 7, 2024 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Third Quarter 2024 Financial Results on November 7, 2024 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, October 31, 2024 — InfuSystem Holdings
September 27, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 27, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (
September 27, 2024	EX-99.1	InfuSystem to Participate in Lytham Partners Fall 2024 Investor Conference on October 1, 2024 Fireside Chat to be held at 3:30pm ET Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Participate in Lytham Partners Fall 2024 Investor Conference on October 1, 2024 Fireside Chat to be held at 3:30pm ET Rochester Hills, Michigan, September 27, 2024 - InfuSystem Holdings, I
September 24, 2024	SC 13D/A	INFU / InfuSystem Holdings, Inc. / SANSONE ADVISORS, LLC Activist Investment SC 13D/A 1 d1148331313d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* InfuSystem Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45685K102 (CUSIP Number) Christopher Sansone c/o Sansone Advisors, LLC 151 Bodman Place, Suite 100 Red Bank, New Jer
September 12, 2024	EX-99.1	Investor Presentation September 12, 2024 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-lo Investor Presentation September 12, 2024 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
September 12, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 12, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (
September 11, 2024	EX-99.1	InfuSystem and Sanara MedTech Inc. Announce Exclusive United States Distribution Agreement with ChemoMouthpiece, LLC Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem and Sanara MedTech Inc. Announce Exclusive United States Distribution Agreement with ChemoMouthpiece, LLC Rochester Hills, Michigan, September 11, 2024 - InfuSystem Holdings, Inc. (NYSE Ameri
September 11, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 11, 2024 InfuSystem Hol UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 11, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (
September 4, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 4, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
September 4, 2024	EX-99.1	InfuSystem to Participate in Lake Street’s 8th Annual Best Ideas Growth (BIG8) Conference September 12, 2024 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Participate in Lake Street’s 8th Annual Best Ideas Growth (BIG8) Conference September 12, 2024 Rochester Hills, Michigan, September 4, 2024 - InfuSystem Holdings, Inc. (NYSE American: INFU
August 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2024 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-35020 INF
August 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
August 8, 2024	EX-99.1	InfuSystem Reports Second Quarter 2024 Financial Results Record Net Revenues of $33.7 million Representing 6% Growth from the Prior Year Reaffirms Full-Year 2024 Guidance Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports Second Quarter 2024 Financial Results Record Net Revenues of $33.7 million Representing 6% Growth from the Prior Year Reaffirms Full-Year 2024 Guidance Rochester Hills, Michigan, August 8, 2024 – InfuSyste
August 6, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 6, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
August 6, 2024	EX-99.1	InfuSystem Announces Distribution Agreement with Smith+Nephew for Negative Pressure Wound Therapy System and First Shipment of NPWT Systems Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Announces Distribution Agreement with Smith+Nephew for Negative Pressure Wound Therapy System and First Shipment of NPWT Systems Rochester Hills, Michigan, August 6, 2024 - InfuSystem Holding
August 2, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 2, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
August 2, 2024	EX-99.1	InfuSystem to Report Second Quarter 2024 Financial Results on August 8, 2024 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Second Quarter 2024 Financial Results on August 8, 2024 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, August 2, 2024 — InfuSystem Holdings, I
June 12, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 12, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commi
June 12, 2024	EX-99.1	Investor Presentation June 12, 2024 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking Investor Presentation June 12, 2024 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as am
June 4, 2024	EX-99.1	InfuSystem to Present at Sidoti Small Cap Conference on June 12, 2024 Investor Presentation to be held at 8:30 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Present at Sidoti Small Cap Conference on June 12, 2024 Investor Presentation to be held at 8:30 a.m. Eastern Time Rochester Hills, Michigan, June 4, 2024 - InfuSystem Holdings, Inc. (NYSE
June 4, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 4, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commis
May 20, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 16, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commis
May 20, 2024	EX-99.1	InfuSystem Announces $20 Million Stock Repurchase Program Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Announces $20 Million Stock Repurchase Program Rochester Hills, Michigan, May 20, 2024 - InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national he
May 17, 2024	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 16, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commis
May 9, 2024	EX-99.1	InfuSystem Reports First Quarter 2024 Financial Results Record Net Revenues of $32.0 million Representing 5% Growth from the Prior Year Gross Profit increased 10% - Gross Margin of 51.5%, an increase of 2.3% Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports First Quarter 2024 Financial Results Record Net Revenues of $32.0 million Representing 5% Growth from the Prior Year Gross Profit increased 10% - Gross Margin of 51.5%, an increase of 2.3% Rochester Hills,
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2024 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-35020 IN
May 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commiss
May 2, 2024	EX-99.1	InfuSystem to Report First Quarter 2024 Financial Results on May 9, 2024 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report First Quarter 2024 Financial Results on May 9, 2024 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, May 2, 2024 — InfuSystem Holdings, Inc. (NY
May 2, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commiss
April 23, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
April 10, 2024	EX-21.1	Subsidiaries of InfuSystem Holdings, Inc. EXHIBIT 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization InfuSystem, Inc. Delaware 1
April 10, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35020 INFUSYSTEM
April 10, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
April 10, 2024	EX-97.1	InfuSystem Holdings, Inc. Policy for the Recovery of Erroneously Awarded Compensation, dated as of October 2, 2023 EXHIBIT 97.1 INFUSYSTEM HOLDINGS, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1.Purpose. The purpose of this Policy is to describe certain circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to the Company Group. Each Executive Officer must sign an acknowledgement or other agreement pursuant to which such Executive Off
April 3, 2024	EX-99.1	InfuSystem Receives Notice from NYSE American Regarding Late Filing of Annual Report on Form 10-K Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Receives Notice from NYSE American Regarding Late Filing of Annual Report on Form 10-K Rochester Hills, Michigan, April 3, 2024 - InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem”
April 3, 2024	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 2, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commi
March 14, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 14, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
March 14, 2024	EX-99.1	InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2023 Full Year 2023 vs. Full Year 2022: Record Net Revenues: $125.8 million, a 14% increase Patient Services Revenue: $76.5 million - Device Solutions Revenue: $4 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2023 Full Year 2023 vs. Full Year 2022: Record Net Revenues: $125.8 million, a 14% increase Patient Services Revenue: $76.5 million - De
March 14, 2024	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended:
March 8, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 8, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commi
March 8, 2024	EX-99.1	COOPERATION AGREEMENT Exhibit 99.1 COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”) is made as of March 8, 2024, by and among InfuSystem Holdings, Inc. (the “Company”), R. Rimmy Malhotra (“Malhotra”), and Nicoya Capital LLC (“Nicoya”); each a “Party” and, collectively, the “Parties.” WHEREAS, Malhotra has been serving as a member of the Company’s board of directors (the “Board”) since September 20, 2
March 8, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 8, 2024 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commi
March 8, 2024	EX-99.1	InfuSystem to Report Fourth Quarter and Full Year 2023 Financial Results on March 14, 2024 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Fourth Quarter and Full Year 2023 Financial Results on March 14, 2024 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, March 8, 2024 — InfuSyste
February 13, 2024	SC 13G	INFU / InfuSystem Holdings, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01181-infusystemholdingsin.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: InfuSystem Holdings Inc Title of Class of Securities: Common Stock CUSIP Number: 45685K102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule purs
November 29, 2023	SC 13D/A	INFU / InfuSystem Holdings Inc / SANSONE ADVISORS, LLC Activist Investment SC 13D/A 1 d1089097413d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* InfuSystem Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45685K102 (CUSIP Number) Christopher Sansone c/o Sansone Advisors, LLC 151 Bodman Place, Suite 100 Red Bank, New Jer
November 28, 2023	EX-99.1	InfuSystem to Present at Sidoti Small-Cap Virtual Conference on December 6, 2023 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Present at Sidoti Small-Cap Virtual Conference on December 6, 2023 Rochester Hills, Michigan, November 28, 2023 - InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Comp
November 28, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 28, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
November 16, 2023	EX-99.1	Investor Presentation November 9, 2023 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-look Investor Presentation November 9, 2023 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
November 16, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 16, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2023 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-3502
November 9, 2023	EX-10.1	to Master Services Agreement dated as of April 28, 2022 between InfuSystem, Inc. and GE Precision Healthcare LLC. Exhibit 10.1 Master Services Agreement - InfuSystem AMENDMENT 1 This Amendment 1 (this “Amendment”) to the Master Service Agreement dated April 25, 2022 (the “Agreement”) by and between InfuSystem Inc. having an office located at 3851 West Hamlin Road, Rochester Hills, Michigan 48309 (“Supplier”), and GE Precision Healthcare LLC having an office located at 3000 N Grandview Blvd, Waukesha, WI 53188
November 9, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 9, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
November 9, 2023	EX-99.1	InfuSystem to Participate at 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Participate at 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023 Rochester Hills, Michigan, November 9, 2023 - InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSys
November 7, 2023	EX-99.1	InfuSystem Reports Third Quarter 2023 Financial Results Record Net Revenues of $31.9 million Representing 17% Growth from the Prior Year Operating Income Increased 80% - Net Income Increased 56% - Adjusted EBITDA Increased 11% Raising Full Year 2023 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports Third Quarter 2023 Financial Results Record Net Revenues of $31.9 million Representing 17% Growth from the Prior Year Operating Income Increased 80% - Net Income Increased 56% - Adjusted EBITDA Increased 1
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
October 31, 2023	EX-99.1	InfuSystem to Report Third Quarter 2023 Financial Results on November 7, 2023 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Third Quarter 2023 Financial Results on November 7, 2023 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, October 31, 2023 — InfuSystem Holdings
October 31, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 31, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
September 14, 2023	EX-99.1	Investor Presentation September 14, 2023 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-lo Investor Presentation September 14, 2023 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
September 14, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 14, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (
September 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 5, 2023 InfuSystem Hold UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 5, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
September 5, 2023	EX-99.1	InfuSystem to Participate in Lake Street’s 7th Annual Best Ideas Growth (BIG7) Conference September 14, 2023 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Participate in Lake Street’s 7th Annual Best Ideas Growth (BIG7) Conference September 14, 2023 Rochester Hills, Michigan, September 5, 2023 - InfuSystem Holdings, Inc. (NYSE American: INFU
August 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2023 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-35020 INF
August 3, 2023	EX-99.1	InfuSystem Reports Second Quarter 2023 Financial Results Record Net Revenues of $31.7 million Representing 17% Growth From the Prior Year Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports Second Quarter 2023 Financial Results Record Net Revenues of $31.7 million Representing 17% Growth From the Prior Year Rochester Hills, Michigan, August 3, 2023 – InfuSystem Holdings, Inc. (NYSE American:
August 3, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 3, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
July 28, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 26, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 26, 2023 (June 30, 2023) InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporati
July 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 27, 2023 InfuSystem Holdings UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 27, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commi
July 27, 2023	EX-99.1	InfuSystem to Report Second Quarter 2023 Financial Results on August 3, 2023 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Second Quarter 2023 Financial Results on August 3, 2023 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, July 27, 2023 — InfuSystem Holdings, In
July 7, 2023	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 30, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commi
July 7, 2023	EX-16.1	Letter to Securities and Exchange Commission from BDO USA, LLP, Exhibit 16.1 July 6, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on June 30, 2023, to be filed by our former client, InfuSystem Holdings, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours, /s/
June 22, 2023	EX-99.1	InfuSystem Set to Join Russell 3000® Index Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Set to Join Russell 3000® Index Rochester Hills, Michigan, June 21, 2023 - InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care serv
June 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 21, 2023 InfuSystem Holdings UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 21, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commi
June 6, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) InfuSystem Holdings, Inc.
June 6, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 infu-20230606xexx107xcalcu.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) InfuSystem Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Pr
June 6, 2023	S-8	As filed with the Securities and Exchange Commission on June 6, 2023 As filed with the Securities and Exchange Commission on June 6, 2023 Registration No.
June 6, 2023	S-8	As filed with the Securities and Exchange Commission on June 6, 2023 As filed with the Securities and Exchange Commission on June 6, 2023 Registration No.
May 25, 2023	EX-10.2	InfuSystem Holdings, Inc. 2023 Employee Stock Purchase Plan Exhibit 10.2 INFUSYSTEM HOLDINGS, INC. 2023 EMPLOYEE STOCK PURCHASE PLAN Article 1. Purpose The purpose of the InfuSystem Holdings, Inc. 2023 Employee Stock Purchase Plan (the “Plan”) is to provide employees of InfuSystem Holdings, Inc. (the “Company”) and its Affiliates with an opportunity to become owners of the Company by purchasing shares of the Company’s common stock through payroll deduction
May 25, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 16, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commis
May 25, 2023	EX-10.1	First Amendment to the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 25, 2023). Exhibit 10.1 FIRST AMENDMENT TO THE INFUSYSTEM HOLDINGS, INC. 2021 EQUITY INCENTIVE PLAN THIS FIRST AMENDMENT to the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (the "Plan") was adopted by the Board of Directors (the “Board”) on February 15, 2023 and approved by the stockholders of InfuSystem Holdings, Inc. (the “Company”) on May 16, 2023. WHEREAS, the Company maintains the Plan to (i) at
May 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 16, 2023 InfuSystem Holdings, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 16, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commis
May 11, 2023	EX-99.1	Investor Presentation May 11, 2023 l (NYSE American: INFU) Helping People Live Healthier and Longer Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking exhibit9911q23investorpr Investor Presentation May 11, 2023 l (NYSE American: INFU) Helping People Live Healthier and Longer Lives Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exc
May 11, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 11, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commis
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2023 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-35020 IN
May 9, 2023	EX-10.1	, dated August 4, 2022, by and between the Company and R. Rimmy Malhotra (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q (File No. 1-35020) filed on May 9, 2023). Exhibit 10.1 NON-DISCLOSURE AGREEMENT FOR POTENTIAL DIRECTOR CANDIDATE This non-disclosure agreement (this “Agreement”) is made as of August 4, 2022, by and between InfuSystem Holdings, Inc. (the “Company”) and R. Rimmy Malhotra (the “Candidate”, and together with the Company, the “Parties”). WHEREAS, the Candidate wishes to be considered by the Company, and the Company invites the Candidate to be
May 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 5, 2023 InfuSystem Holdings, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 5, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commiss
May 5, 2023	EX-99.1	InfuSystem to Present at Sidoti Micro-Cap Virtual Conference on May 11, 2023 Investor Presentation to be held at 9:15 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Present at Sidoti Micro-Cap Virtual Conference on May 11, 2023 Investor Presentation to be held at 9:15 a.m. Eastern Time Rochester Hills, Michigan, May 5, 2023 - InfuSystem Holdings, Inc.
May 4, 2023	EX-99.1	InfuSystem Reports First Quarter 2023 Financial Results Record Net Revenues of $30.4 million Representing 13% Growth From the Prior Year Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports First Quarter 2023 Financial Results Record Net Revenues of $30.4 million Representing 13% Growth From the Prior Year Rochester Hills, Michigan, May 4, 2023 – InfuSystem Holdings, Inc. (NYSE American: INFU
May 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 4, 2023 InfuSystem Holdings, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 4, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commiss
May 2, 2023	EX-10.1	First Amendment to Credit Agreement dated as of April 21, 2023 by and among InfuSystem Holdings, Inc., InfuSystem Holdings USA, Inc., InfuSystem, Inc., First Biomedical, Inc., IFC LLC, the lenders party thereto and JPMorgan Chase Bank, N.A. as administrative agent for the lenders (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 2, 2023). Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of April 26, 2023 (this “Amendment”), is by and among INFUSYSTEM HOLDINGS, INC., INFUSYSTEM HOLDINGS USA, INC., INFUSYSTEM, INC., FIRST BIOMEDICAL, INC., and IFC LLC (collectively, the "Borrowers"), the lenders party hereto (collectively, the “Lenders” and individually, a “Lender”), and JPMORGAN CHA
May 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 26, 2023 InfuSystem Holding UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 26, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
April 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 27, 2023 InfuSystem Holding UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 27, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
April 27, 2023	EX-99.1	InfuSystem to Report First Quarter 2023 Financial Results on May 4, 2023 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report First Quarter 2023 Financial Results on May 4, 2023 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, April 27, 2023 — InfuSystem Holdings, Inc.
April 25, 2023	EX-99.1	InfuSystem Announces Distribution Agreement with Genadyne for Negative Pressure Wound Therapy Systems Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Announces Distribution Agreement with Genadyne for Negative Pressure Wound Therapy Systems Rochester Hills, Michigan, April 25, 2023 - InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSy
April 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 25, 2023 InfuSystem Holding UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 25, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
April 10, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
March 28, 2023	SC 13D/A	INFU / InfuSystem Holdings Inc / Shuda Scott - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* InfuSystem Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45685K102 (CUSIP Number) Scott A Shuda Meridian OHC Partners, LP 425 Weed Street New Canaan, CT 06840 (Name, Address and Telephone Number
March 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 24, 2023 InfuSystem Holding UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 24, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
March 16, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35020 INFUSYSTEM
March 16, 2023	EX-21.1	Subsidiaries of InfuSystem Holdings, Inc. EXHIBIT 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization InfuSystem, Inc. California First Biomedical, Inc. Kansas IFC, LLC Delaware InfuSystem Holdings USA, Inc. Delaware 1
March 15, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 15, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
March 15, 2023	EX-99.1	InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2022 Full Year 2022 vs. Full Year 2021: Record Net Revenues: $109.9 million, a 7% increase ITS Revenue: $68.9 million - DME Revenue: $41.0 million, increases of 5 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2022 Full Year 2022 vs. Full Year 2021: Record Net Revenues: $109.9 million, a 7% increase ITS Revenue: $68.9 million - DME Revenue: $41
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 13, 2023 InfuSystem Holding UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 13, 2023 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
March 13, 2023	EX-99.1	InfuSystem to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, March 13, 2023 — InfuSyst
November 10, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 10, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
November 10, 2022	EX-99.1	InfuSystem to Participate at 13th Annual Craig-Hallum Alpha Select Conference on November 17, 2022 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Participate at 13th Annual Craig-Hallum Alpha Select Conference on November 17, 2022 Rochester Hills, Michigan, November 10, 2022 - InfuSystem Holdings, Inc. (NYSE American: INFU) (?InfuSy
November 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 8, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
November 8, 2022	EX-99.1	InfuSystem Reports Third Quarter 2022 Financial Results Record Net Revenues of $27.3 million and Record ITS revenues of $17.4 million Operating Income increased $1.3 million and Net Income increased $0.9 million Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports Third Quarter 2022 Financial Results Record Net Revenues of $27.3 million and Record ITS revenues of $17.4 million Operating Income increased $1.3 million and Net Income increased $0.9 million Rochester Hi
November 8, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 8, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-3502
November 8, 2022	EX-99.1	Investor Presentation NOVEMBER 8, 2022 l (NYSE American: INFU) Enabling Continuity of Care for Patients, From the Clinic to Their Home Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this pres Investor Presentation NOVEMBER 8, 2022 l (NYSE American: INFU) Enabling Continuity of Care for Patients, From the Clinic to Their Home Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, business plans, objectives and prospects, our share repurchase program and capital allocation strategy, future operating or financial performance and guidance.
November 3, 2022	EX-99.1	InfuSystem and Sanara MedTech Announce Wound Therapy Partnership Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem and Sanara MedTech Announce Wound Therapy Partnership Rochester Hills, Michigan, November 3, 2022 - InfuSystem Holdings, Inc. (NYSE American: INFU) (?InfuSystem? or the ?Company?) and Sanara
November 3, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 3, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
November 2, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 2, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
November 2, 2022	EX-99.1	InfuSystem to Report Third Quarter 2022 Financial Results on November 8, 2022 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Third Quarter 2022 Financial Results on November 8, 2022 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, November 2, 2022 ? InfuSystem Holdings
September 23, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 20, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (
September 23, 2022	EX-99.1	InfuSystem Appoints R. Rimmy Malhotra to the Board of Directors Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Appoints R. Rimmy Malhotra to the Board of Directors Rochester Hills, Michigan, September 23, 2022 - InfuSystem Holdings, Inc. (NYSE American: INFU) (?InfuSystem? or the ?Company?), a leading
September 13, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 8, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
September 13, 2022	EX-99.1	Investor Presentation SEPTEMBER 8, 2022 l (NYSE American: INFU) Enabling Continuity of Care for Patients, From the Clinic to Their Home Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this pre Investor Presentation SEPTEMBER 8, 2022 l (NYSE American: INFU) Enabling Continuity of Care for Patients, From the Clinic to Their Home Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, business plans, objectives and prospects, our share repurchase program and capital allocation strategy, future operating or financial performance and guidance.
September 7, 2022	EX-99.1	InfuSystem to Participate in Lake Street’s 6th Annual Best Ideas Growth (BIG6) Conference September 14, 2022 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Participate in Lake Street?s 6th Annual Best Ideas Growth (BIG6) Conference September 14, 2022 Rochester Hills, Michigan, September 7, 2022 - InfuSystem Holdings, Inc. (NYSE American: INFU
September 7, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 7, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
August 4, 2022	EX-99.1	InfuSystem Reports Second Quarter 2022 Financial Results Net Revenues increased 9% to $27 million; ITS revenues increased 6% and DME revenues increased 15% Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports Second Quarter 2022 Financial Results Net Revenues increased 9% to $27 million; ITS revenues increased 6% and DME revenues increased 15% Rochester Hills, Michigan, August 4, 2022 ? InfuSystem Holdings, Inc
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-35020 INF
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 4, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
August 4, 2022	EX-10.1	Form of Restricted Stock Unit Agreement (Performance-based Vesting) under the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on August 4, 2022). Exhibit 10.1 FORM OF RESTRICTED STOCK UNIT AGREEMENT INFUSYSTEM HOLDINGS, INC. 2021 EQUITY INCENTIVE PLAN Restricted stock units are hereby granted to ("Grantee") by InfuSystem Holdings, Inc. a Delaware corporation (the "Company") pursuant to this Restricted Stock Unit Agreement (this "Agreement"). The restricted stock units granted pursuant to this Agreement (the "RSUs") are subject to the terms
July 29, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 29, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commi
July 29, 2022	EX-99.1	InfuSystem to Report Second Quarter 2022 Financial Results on August 4, 2022 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Second Quarter 2022 Financial Results on August 4, 2022 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, July 29, 2022 ? InfuSystem Holdings, In
June 14, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 14, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commi
June 14, 2022	EX-99.1	InfuSystem and Ventis Pharma Announce National Sales and Marketing Agreement for Pain Management The Company will offer Ventis Pharma’s patented local anesthetic compound, Endura-KitTM for post-operative surgical and chronic pain management Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem and Ventis Pharma Announce National Sales and Marketing Agreement for Pain Management The Company will offer Ventis Pharma’s patented local anesthetic compound, Endura-KitTM for post-operativ
May 26, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 26, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commis
May 26, 2022	EX-99.1	InfuSystem to Participate at Craig-Hallum 19th Annual Institutional Investor Conference on Wednesday, June 1, 2022 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Participate at Craig-Hallum 19th Annual Institutional Investor Conference on Wednesday, June 1, 2022 Rochester Hills, Michigan, May 26, 2022 - InfuSystem Holdings, Inc. (NYSE American: INF
May 17, 2022	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 17, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commis
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-35020 IN
May 5, 2022	EX-99.1	InfuSystem Reports First Quarter 2022 Financial Results Signed 3-year Master Service Agreement with Leading Global Medical Technology and Diagnostic Company – Estimated Potential Annual Revenue of $10 Million to $12 Million Revenue Growth of 9% - Dri Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports First Quarter 2022 Financial Results Signed 3-year Master Service Agreement with Leading Global Medical Technology and Diagnostic Company – Estimated Potential Annual Revenue of $10 Million to $12 Million
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 5, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Commiss
April 28, 2022	EX-99.1	InfuSystem Announces Master Service Agreement with Leading Global Healthcare Technology and Diagnostic Company Preferred National Service Agreement to provide service and repair to fleet of more than 300,000 pumps in North America; Estimated $10-$12 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Announces Master Service Agreement with Leading Global Healthcare Technology and Diagnostic Company Preferred National Service Agreement to provide service and repair to fleet of more than 30
April 28, 2022	EX-10.1	Master Services Agreement dated as of April 28, 2022 between InfuSystem, Inc. and GE Precision Healthcare LLC. Exhibit 10.1 INFUSYSTEM, INC. Master Services Agreement Table of Contents Page A.SCOPE OF AGREEMENT 1 B.STATEMENTS OF WORK/DESCRIPTION OF SERVICES. 1 C.CHANGE REQUESTS/ORDERS 1 D.ADDITIONAL TERMS AND CONDITIONS 2 1.Term and Termination. 2 2.Representations, Warranties and Covenants. 3 3.Indemnification 5 4.Limitation of Liability; Disclaimer of Special Damages; Exclusions 6 5.Confidentiality and P
April 28, 2022	EX-99.1	InfuSystem to Report First Quarter 2022 Financial Results on May 5, 2022 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report First Quarter 2022 Financial Results on May 5, 2022 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, April 28, 2022 ? InfuSystem Holdings, Inc.
April 28, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 28, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
April 28, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 28, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
April 4, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
March 23, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 23, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Comm
March 23, 2022	EX-99.1	Investor Presentation March 23, 2022 l (NYSE American: INFU) Enabling Continuity of Care for Patients, From the Clinic to Their Home Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presen Investor Presentation March 23, 2022 l (NYSE American: INFU) Enabling Continuity of Care for Patients, From the Clinic to Their Home Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, business plans, objectives and prospects, our share repurchase program and capital allocation strategy, future operating or financial performance and guidance.
March 15, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35020 INFUSYSTEM
March 15, 2022	EX-21.1	Subsidiaries of InfuSystem Holdings, Inc. EXHIBIT 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization InfuSystem, Inc. California First Biomedical, Inc. Kansas IFC, LLC Delaware InfuSystem Holdings USA, Inc. Delaware 1
February 22, 2022	EX-99.1	InfuSystem Announces Agreement with Solo-Dex for Continuous Peripheral Nerve Block Catheters Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Announces Agreement with Solo-Dex for Continuous Peripheral Nerve Block Catheters Rochester Hills, Michigan, February 22, 2022 - InfuSystem Holdings, Inc. (NYSE American: INFU), (?InfuSystem?
February 22, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 22, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
February 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 10, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
February 10, 2022	EX-99.1	InfuSystem Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021 Full Year 2021 vs. Full Year 2020: Net Revenues: $102.4 million, a 5% increase Net Income: $1.4 million, Adjusted EBITDA: $24.0 million Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021 Full Year 2021 vs. Full Year 2020: Net Revenues: $102.4 million, a 5% increase Net Income: $1.4 million, Adjusted EBITD
February 9, 2022	EX-99.1	InfuSystem to Report Preliminary Fourth Quarter and Full Year 2021 Financial Results on February 10, 2022 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Preliminary Fourth Quarter and Full Year 2021 Financial Results on February 10, 2022 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, February 9
February 9, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 9, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
January 13, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 13, 2022 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
January 13, 2022	EX-99.1	InfuSystem to Present at Sidoti Winter Virtual Investor Conference on Wednesday, January 19, 2022 Investor Presentation to be held at 8:30 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Present at Sidoti Winter Virtual Investor Conference on Wednesday, January 19, 2022 Investor Presentation to be held at 8:30 a.m. Eastern Time Rochester Hills, Michigan, January 13, 2022 -
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-3502
November 15, 2021	EX-99.1	InfuSystem Reports Third Quarter 2021 Financial Results Selected as Supplier of Infusion Pump Biomedical Services for Leading Global Medical Technology and Diagnostic Equipment Company Worth Expected $14 Million to $15 Million in Annual Revenue Poten Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports Third Quarter 2021 Financial Results Selected as Supplier of Infusion Pump Biomedical Services for Leading Global Medical Technology and Diagnostic Equipment Company Worth Expected $14 Million to $15 Milli
November 15, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 15, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
November 15, 2021	EX-33.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Exhibit 32.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of InfuSystem Holdings, Inc., a D
November 15, 2021	EX-99.1	Investor Presentation NOVEMBER 15, 2021 l (NYSE American: INFU) Enabling Continuity of Care for Patients, From the Clinic to Their Home Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this pre Investor Presentation NOVEMBER 15, 2021 l (NYSE American: INFU) Enabling Continuity of Care for Patients, From the Clinic to Their Home Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, business plans, objectives and prospects, our share repurchase program and capital allocation strategy, future operating or financial performance and guidance.
November 15, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 15, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
November 3, 2021	EX-99.1	InfuSystem to Report Third Quarter 2021 Financial Results on November 15, 2021 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Third Quarter 2021 Financial Results on November 15, 2021 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, November 3, 2021 ? InfuSystem Holding
November 3, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 3, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
November 2, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 2, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (Co
November 2, 2021	EX-99.1	InfuSystem Announces Pain Management Service Agreement with Leading U.S. Health Care Provider Exclusive 3-year agreement providing electronic infusion pumps to treat post-surgical pain Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Announces Pain Management Service Agreement with Leading U.S. Health Care Provider Exclusive 3-year agreement providing electronic infusion pumps to treat post-surgical pain Rochester Hills,
September 8, 2021	EX-99.1	InfuSystem to Participate in Lake Street’s 5th Annual Best Ideas Growth (BIG5) Conference September 14, 2021 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Participate in Lake Street?s 5th Annual Best Ideas Growth (BIG5) Conference September 14, 2021 Rochester Hills, Michigan, September 8, 2021?InfuSystem Holdings, Inc. (NYSE American: INFU)
September 8, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 8, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35020 (C
August 12, 2021	EX-99.1	InfuSystem Reports Second Quarter 2021 Financial Results Launched Fourth ITS Therapy - Lymphedema Announced $20 million Stock Repurchase Program Updates Guidance for 2021 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports Second Quarter 2021 Financial Results Launched Fourth ITS Therapy - Lymphedema Announced $20 million Stock Repurchase Program Updates Guidance for 2021 Rochester Hills, Michigan, August 12, 2021 ? InfuSyst
August 12, 2021	EX-99.1	InfuSystem Holdings, Inc. Investor Presentation dated August 12, 2021. Exhibit 99.1
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-35020 INF
August 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35020 20-3341405 (State or other jurisdiction of incorporation or organiz
August 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35020 20-3341405 (State or other jurisdiction of incorporation or organiz
August 5, 2021	EX-99.1	InfuSystem to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021 Investor Conference Call to be held 9:00 a.m. Eastern Time EX-99.1 2 ex271451.htm EXHIBIT 99.1 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Mi
August 5, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35020 20-3341405 (State or other jurisdiction of incorporation or organiza
July 6, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35020 20-3341405 (State or other jurisdiction of incorporation or organizati
July 6, 2021	EX-99.1	InfuSystem Holdings, Inc. Investor Presentation dated July 6, 2021. EX-99.1 2 ex260840.htm EXHIBIT 99.1 Exhibit 99.1
June 30, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35020 20-3341405 (State or other jurisdiction of incorporation or organizat
June 30, 2021	EX-99.1	InfuSystem Announces $20 Million Stock Repurchase Program Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Announces $20 Million Stock Repurchase Program Rochester Hills, Michigan, June 30, 2021?InfuSystem Holdings, Inc. (NYSE American: INFU) (?InfuSystem? or the ?Company?), a leading national health care service provi
June 29, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35020 20-3341405 (State or other jurisdiction of incorporation or organizat
June 29, 2021	EX-99.1	InfuSystem Enters Lymphedema Therapy Market Providing pneumatic compression devices for last-mile patient care EX-99.1 2 ex260362.htm EXHIBIT 99.1 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Enters Lymphedema Therapy Market Providing pneumatic compression devices for last-mile patient care Rochester Hills, Michigan, June 29, 2021—InfuSystem Holdings, Inc. (NYSE Amer
May 27, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35020 20-3341405 (State or other jurisdiction of incorporation or organizati
May 27, 2021	EX-99.1	InfuSystem to Participate at Craig-Hallum 18th Annual Institutional Investor Conference June 2, 2021 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Participate at Craig-Hallum 18th Annual Institutional Investor Conference June 2, 2021 Rochester Hills, Michigan, May 27, 2021 ? InfuSystem Holdings, Inc. (NYSE American: INFU), (?InfuSyst
May 24, 2021	EX-10.8	First Amended and Restated Employment Agreement, dated May 24, 2021, by and between the Company and Jeannine Sheehan (incorporated by reference to Exhibit 10.8 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021). Exhibit 10.8 FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amended and Restated Employment Agreement (?Agreement?) is made as of the Effective Date between InfuSystem Holdings, Inc., a Delaware corporation (the ?Company?), and Jeannine Sheehan, an individual (?Employee?). WHEREAS, the Company wishes to retain Employee?s services to work for the Company as its Executive Vice President
May 24, 2021	EX-10.7	First Amended and Restated Employment Agreement, dated May 24, 2021, by and between the Company and Carrie Lachance (incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021). Exhibit 10.7 FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amended and Restated Employment Agreement (?Agreement?) is made as of the Effective Date between InfuSystem Holdings, Inc., a Delaware corporation (the ?Company?), and Carrie Lachance, an individual (?Employee?). WHEREAS, the Company wishes to retain Employee?s services to work for the Company as its President and Chief Operat
May 24, 2021	EX-10.5	First Amended and Restated Employment Agreement, dated May 24, 2021, by and between the Company and Richard DiIorio (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021). EX-10.5 6 ex252608.htm EXHIBIT 10.5 Exhibit 10.5 FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amended and Restated Employment Agreement (“Agreement”) is made as of the Effective Date between InfuSystem Holdings, Inc., a Delaware corporation (the “Company”), and Richard A. DiIorio, an individual (“Employee”). WHEREAS, the Company wishes to retain Employee’s services to work for the Co
May 24, 2021	EX-10.1	Form of Nonqualified Stock Option Agreement (Non-employee Directors) under the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021). EX-10.1 2 ex252604.htm EXHIBIT 10.1 Exhibit 10.1 Non-Employee Directors NONQUALIFIED STOCK OPTION AGREEMENT INFUSYSTEM HOLDINGS, INC. 2021 EQUITY INCENTIVE PLAN This Nonqualified Stock Option Agreement (this "Agreement") is made and entered into as of , 20, by and between InfuSystem Holdings, Inc., a Delaware corporation (the "Company") and , ("Director"). Grant Date: Exercise Price per Share: Num
May 24, 2021	EX-10.9	First Amended and Restated Employment Agreement, dated May 24, 2021, by and between the Company and Tom Ruiz (incorporated by reference to Exhibit 10.9 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021). Exhibit 10.9 FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amended and Restated Employment Agreement (?Agreement?) is made as of the Effective Date between InfuSystem Holdings, Inc., a Delaware corporation (the ?Company?), and Thomas Ruiz, an individual (?Employee?). WHEREAS, the Company wishes to retain Employee?s services to work for the Company as its Executive Vice President and C
May 24, 2021	EX-10.3	Form of Restricted Stock Unit Agreement (Time-based Vesting) under the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021). EX-10.3 4 ex252606.htm EXHIBIT 10.3 Exhibit 10.3 Time-based Vesting RESTRICTED STOCK UNIT AGREEMENT INFUSYSTEM HOLDINGS, INC. 2021 EQUITY INCENTIVE PLAN Restricted stock units are hereby granted to ("Grantee") by InfuSystem Holdings, Inc. a Delaware corporation (the "Company") pursuant to this Restricted Stock Unit Agreement (this "Agreement"). The restricted stock units granted pursuant to this A
May 24, 2021	EX-10.6	First Amended and Restated Employment Agreement, dated May 24, 2021, by and between the Company and Barry Steele (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021). EX-10.6 7 ex252609.htm EXHIBIT 10.6 Exhibit 10.6 FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amended and Restated Employment Agreement (“Agreement”) is made as of the Effective Date between InfuSystem Holdings, Inc., a Delaware corporation (the “Company”), and Barry Steele, an individual (“Employee”). WHEREAS, the Company wishes to retain Employee’s services to work for the Company
May 24, 2021	EX-10.2	Form of Nonqualified Stock Option Agreement (Employees) under the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021). Exhibit 10.2 Employees NONQUALIFIED STOCK OPTION AGREEMENT INFUSYSTEM HOLDINGS, INC. 2021 EQUITY INCENTIVE PLAN This Nonqualified Stock Option Agreement (this "Agreement") is made and entered into as of , 20, by and between InfuSystem Holdings, Inc., a Delaware corporation (the "Company") and , ("Employee"). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: SECTION 1.
May 24, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35020 20-3341405 (State or other jurisdiction of incorporation or organizati
May 24, 2021	EX-10.4	Form of Restricted Stock Unit Agreement (Performance-based Vesting) under the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 24, 2021). Exhibit 10.4 Performance-based Vesting RESTRICTED STOCK UNIT AGREEMENT INFUSYSTEM HOLDINGS, INC. 2021 EQUITY INCENTIVE PLAN Restricted stock units are hereby granted to ("Grantee") by InfuSystem Holdings, Inc. a Delaware corporation (the "Company") pursuant to this Restricted Stock Unit Agreement (this "Agreement"). The restricted stock units granted pursuant to this Agreement (the "RSUs") are sub
May 18, 2021	S-8	As filed with the Securities and Exchange Commission on May 18, 2021 As filed with the Securities and Exchange Commission on May 18, 2021 Registration No.
May 18, 2021	EX-99.1	InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company’s Registration Statement on Form S-8 (File No. 333-256231) filed on May 18, 2021). Exhibit 99.1 INFUSYSTEM HOLDINGS, INC. 2021 EQUITY INCENTIVE PLAN SECTION 1. PURPOSE OF THE PLAN The name of this plan is the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (the "Plan"). The purposes of the Plan are to advance the interest of InfuSystem Holdings, Inc. (the "Company") and its stockholders by (i) enabling the Company and any Affiliate to attract and retain the types of Employe
May 18, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35020 20-3341405 (State or other jurisdiction of incorporation or organizati
May 10, 2021	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-35020 IN
May 6, 2021	EX-99.1	InfuSystem Reports First Quarter 2021 Financial Results Net Revenues: $24.5 million, a 14% increase Net Income: $0.7 million, a $1.1 million increase, Adjusted EBITDA: $6.2 million, a 51% increase, and Adjusted EBITDA margin of 25.2%, a 6.3% increase Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Reports First Quarter 2021 Financial Results Net Revenues: $24.5 million, a 14% increase Net Income: $0.7 million, a $1.1 million increase, Adjusted EBITDA: $6.2 million, a 51% increase, and Adjusted EBITDA margin
May 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35020 20-3341405 (State or other jurisdiction of incorporation or organizatio
April 29, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35020 20-3341405 (State or other jurisdiction of incorporation or organiza
April 29, 2021	EX-99.1	InfuSystem to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 Investor Conference Call to be held 9:00 a.m. Eastern Time Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 Investor Conference Call to be held 9:00 a.m. Eastern Time Rochester Hills, Michigan, April 29, 2021 ? InfuSystem Holdi
April 21, 2021	EX-99.1	InfuSystem Acquires OB Healthcare Corporation, Expanding DME Services Platform in Acute Care EX-99.1 2 ex242370.htm EXHIBIT 99.1 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem Acquires OB Healthcare Corporation, Expanding DME Services Platform in Acute Care Rochester Hills, Michigan, April 21, 2021 – InfuSystem Holdings, Inc. (NY
April 21, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35020 20-3341405 (State or other jurisdiction of incorporation or organiza
April 5, 2021	DEF 14A	- FORM DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
March 26, 2021	EX-99.1	InfuSystem Holdings, Inc. Investor Presentation dated March 25, 2021. Exhibit 99.1
March 26, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 InfuSystem Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35020 20-3341405 (State or other jurisdiction of incorporation or organiza
March 22, 2021	EX-99.1	InfuSystem to Present at Sidoti’s Spring 2021 Virtual Conference March 25, 2021 Investor Presentation to be held 9:15 a.m. Eastern Time EX-99.1 2 ex235789.htm EXHIBIT 99.1 Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 InfuSystem to Present at Sidoti’s Spring 2021 Virtual Conference March 25, 2021 Investor Presentation to be held 9:15 a.m. Eastern Time Rochester Hills, Michigan, Mar

INFU / InfuSystem Holdings, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Statistik Asas

SEC Filings

SEC Filings (Chronological Order)

Other Listings